Asset scouting for in-licensing opportunities in fibrosis

Challenge: A biotech company focused on developing therapeutics for fibrotic diseases was looking at acquisitions or in-licensing as a way to grow its development pipeline with additional assets....
Learn More

Business plan for opioid overdose detection device

Challenge Our client was a start-up looking to raise external venture capital funding for development of a biosensor for early detection of opioid overdose. The company had drafted a business plan...
Learn More

Commercial viability of a bacterial biomarker test

Challenge A leading UK university and an executive agency of the DoH were collaboratively developing a rapid (30 min) bacterial ID and antimicrobial resistance test platform. The technology...
Learn More

Distressed company analysis for asset scouting

Challenge: Our client was a publicly-traded precision oncology company with whom Alacrita had previously supported with a long-term asset scouting engagement. This cash-rich biotech company wanted to...
Learn More

Regulatory Due Diligence for A-Fib development drug

Challenge: Our client was a US-based venture capital fund, with whom we have a long-standing retainer agreement to provide specialized due diligence support for their fund investment decisions. In...
Learn More

Scouting in-licensing opportunities for a mid-size pharma company

Challenge: A pharmaceutical company with a proprietary clinical trial technology made the strategic decision to diversify their development arm by acquiring and/or in-licensing pharmaceutical...
Learn More

Valuation of a repurposed, male-fertility drug using Monte Carlo

Challenge: A client developing a repurposed drug for use in male fertility asked Alacrita to conduct a valuation for the asset in the US and EU4+UK in support of impending deal negotiations. The...
Learn More

Sales forecast in metastatic colorectal and gastric cancer

Challenge An international oncology drug development company is developing a bispecific product, currently in preclinical development. As an initial evaluation, our client wanted to understand the...
Learn More

Assessing the radiopharma landscape, future demand and competitive dynamics

Challenge A radiopharmaceuticals CDMO with activities in a range of therapeutic and diagnostic compounds including development-stage and commercial products asked Alacrita to assess the landscape and...
Learn More

Bladder cancer: business case assessment

Challenge A group of healthcare investors with a long track record in the industry, but no biotechnology or research background, were interested in licensing a university project aimed at bladder...
Learn More

Clinical, CMC regulatory & CMC manufacturing due diligence

Challenge: An east coast biotechnology company had reached non-binding terms with an overseas company for development and commercialization rights to a novel anti-cancer product with a...
Learn More

Due diligence & product development planning of a collaboration

Challenge: A well-capitalized US biotechnology company was considering entry into the CAR-T space through a license and research collaboration with a leading US university with a distinguished and...
Learn More
Previous
1 ... 3 4 5 6 7 ... 29
Next

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2023 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.